Why it makes sense to start investing early in your career!

Investing for your retirement may not be the most important thing on your mind when you start your career. For most people, investing may not even be on the priority list when they start their career. When you start your career, your saving capacity may not be much in absolute terms, as your salary itself may not be much. But this should not deter you from making investments. This is because the first few years of your earning life has a huge impact on your future finances.

As with anything else in life, investing also benefits with an early start. The earlier you do your retirement planning, the greater will be your return on investment. There are more reasons than one for you to start investing early in your career. Let's look at the various benefits of early investing.

The effect of compounding:
The most important reason for you to start investing early in your career is to get the benefit of compounding. Compound interest works magic for any investor. As you know, compound interest means the interest earned on interest. If you continuously reinvest your earnings, your return on investment will increase exponentially.

When you regularly invest from the start of your career, you are increasing the return you receive on your returns. A monthly investment of as low as Rs.1,000 or Rs.2,000 will have a large impact on your financial position. Let's understand the effect with a few examples:

Example 1: X is 25 years old and has 35 years left for retirement. He starts to invest Rs. 1000 per month for 35 years at a return of 12% per annum. The corpus left with X at the end of 35 years will be Rs. 64 lakhs.

Y is 30 years old and has only 30 years left for retirement. He also starts to invest Rs. 1000 per month. But as he has started investing late in his career, he can invest this amount only for the next 30 years at 12% per annum. The corpus left with Y at the end of 30 years will be Rs. 35 lakhs. This is the difference 5 years of investment has made to the final corpus value. If Y needs the same Rs. 64 lakhs for his retirement, he will need to shell out Rs.1830 per month instead of Rs. 1000.

To understand the wonder of compounding, let's look at another example:
Example 2: Both X and Y are 30 years of age and have 30 years left for retirement. Now, X invests Rs. 2000 every month for the first 15 years at a return of 12% per annum. He totally invests Rs. 3.6 lakhs. At the end of 15 years of his investment, he does not invest further and also does not withdraw the money. His total corpus at the end of 30 years will be close to Rs. 55 lakhs.

Now Y invests only Rs. 1000 per month at a return of 12% per annum. But he invests for 30 years. Y's total investment is also Rs. 3.6 lakhs - same as X's total investment. But his corpus after 30 years is only Rs. 35 lakhs. Thus for the same total investment, X's corpus is much higher than Y's corpus. This is because X had invested more in the initial years and had allowed this money to get compounded for the total period.

Thus, the most important advantage of beginning to invest early in your career is to realise the full benefits of compounding. There are other reasons why it makes sense to start investing early in your career -

Improvement in spending habits: As you begin to save early in your career to start investing, you have lesser disposable cash with you. This helps you in being more prudent and brings about a discipline in your spending habits.
Ability to take risk: Not all of us get our investment options correct the first time. When you begin exploring investment avenues early in your life, you have a greater ability to take risk and experiment, compared to someone who starts investing later. This is because, at a later stage in life, if you realise you do not have sufficient savings; you will be more cautious in your choice of investments.

Money available during emergencies: When you begin to invest early, you would have a comfortable cushion backing you up. Thus, you can be rest assured that your savings will be of use to you in times of need.

Better choices in life: As seen in the examples above, the corpus built by investing early in life is much bigger than the corpus built by someone who starts a little later. As a result of the savings back-up, you can afford a better lifestyle and an improved quality of life, helping to fulfil your financial goals.
Thus, beginning to invest early in your career can help you in building a secure future.

 

 

BankBazaar.com is an online marketplace where you can instantly get the lowest loan rates , compare and apply online for your personal loan , home loan , car loan and credit card from India's leading banks and NBFCs.

Best Canadian Companies To Watch In Right Now

After launching Windows Phone, Microsoft (NASDAQ: MSFT  ) has been very vocal about its ambitions of becoming the No. 3 operating system platform behind Apple (NASDAQ: AAPL  ) and Google (NASDAQ: GOOG  ) . The iOS and Android duopoly strengthened further in the first quarter, gobbling up 92.3% of smartphone market share, according to the most recent estimates out of IDC.

That stated goal would inevitably entail overtaking BlackBerry (NASDAQ: BBRY  ) . The Canadian company's market share has been sliding for years at the hands of iOS and Android, making Microsoft's job a little easier. Well, the software giant has done exactly what it set out to do.

Congratulations, Microsoft.

Source: IDC.

Best Canadian Companies To Watch In Right Now: Canadian National Railway Company(CNI)

Canadian National Railway Company, together with its subsidiaries, engages in the rail and related transportation business in North America. It provides transportation for various goods, including petroleum and chemicals, grain and fertilizers, coal, metals and minerals, forest products, and intermodal and automotive products. The company operates a network of approximately 20,600 route miles of track that spans Canada and mid-America, from the Atlantic and Pacific oceans to the Gulf of Mexico. It serves the ports of Vancouver, Prince Rupert (British Columbia), Montreal, Halifax, New Orleans, and Mobile (Alabama), as well as metropolitan areas of Toronto, Buffalo, Chicago, Detroit, Duluth (Minnesota)/Superior (Wisconsin), Green Bay (Wisconsin), Minneapolis/St. Paul, Memphis, and Jackson (Mississippi), with connections to various points in North America. The company was founded in 1922 and is headquartered in Montreal, Canada.

Advisors' Opinion:

• [By Vodicka]

  Montreal-based Canadian National Railway (CNI) operates
  about 21,000 route-miles of rail that span all the way from the frozen north down to the Mississippi Delta — nearly enough track to wrap around the entire world. Since Canada is one of the largest countries in the world by geography (second only to Russia with an area of about 4 million square miles), the transportation and freight industries are vital and very lucrative parts of the nation’s economy.

  The reason I’m so bullish on CNI right now is that the company is a large player in transporting commodities, including Canada’s exports of timber and metals and imports of energy from the United States. In Canadian National’s latest earnings report in January, the company stated that Q4 shipments grew for coal, grain and fertilizers and petroleum and chemicals — and this is in spite of bad weather and a five-day strike that really messed with CNI’s schedule. Just imagine how CNI will do in the warmer months as the economy continues to improve.

Best Canadian Companies To Watch In Right Now: UniSource Energy Corporation(UNS)

UniSource Energy Corporation engages in the electric generation and energy delivery businesses. The company?s TEP segment generates, transmits, and distributes electricity to approximately 403,000 retail electric customers, including residential, commercial, industrial, and public sector customers in southeastern Arizona. It also sells electricity to other utilities and power marketing entities. As of December 31, 2010, this segment owned or leased 2,245 MW of net generating capacity, as well as owned or participated in electric transmission and distribution system consisting of 512 circuit-miles of 500-kV lines; 1,087 circuit-miles of 345-kV lines; 379 circuit-miles of 138-kV lines; 478 circuit-miles of 46-kV lines; and 2,621 circuit-miles of lower voltage primary lines. TEP segment generates electricity from coal, gas, oil, and solar sources. The company?s UNS Gas segment distributes gas to approximately 146,500 retail customers in Mohave, Yavapai, Coconino, and Navajo c ounties in northern Arizona, as well as Santa Cruz County in southeastern Arizona. As of December 31, 2010, this segment?s transmission and distribution system consisted of approximately 30 miles of steel transmission mains, 4,211 miles of steel and plastic distribution piping, and 136,439 customer service lines. The company?s UNS Electric segment transmits and distributes electricity to approximately 91,000 retail customers consisting of residential, commercial, and industrial customers in Mohave and Santa Cruz counties. As of December 31, 2010, UNS Electric?s transmission and distribution system consisted of approximately 56 circuit-miles of 115-kV transmission lines, 271 circuit-miles of 69-kV transmission lines, and 3,599 circuit-miles of underground and overhead distribution lines. This segment also owns the 65 MW Valencia plant, as well as 39 substations having an installed capacity of 1,788,050 kilovolt amperes. The company was founded in 1902 and is based in Tucson, Arizona.

Advisors' Opinion:

• [By Dirk_Van_Dijk]

  Uni-Select Inc. (UNS-T28.15-0.39-1.37%) will announce its fourth-quarter results for the period ended Dec. 31, 2011, on Thursday. Its stock gained nearly 2 per cent and moved to within a $1 of a year high $29.47 Wednesday.

  ?

10 Best Blue Chip Stocks To Own Right Now: Grupo TMM S.A.(TMM)

Grupo TMM, S.A.B., together with its subsidiaries, operates as an integrated logistics and transportation company in Mexico. The company offers maritime transportation services, including offshore vessels, which offer transportation and other services to the Mexican offshore oil industry; tankers that transport petroleum products in Mexican waters; parcel tankers, which transport liquid chemical and vegetable oil cargos from and to the United States and Mexico; and tugboats that provide towing services at the port of Manzanillo, Mexico. It operates a fleet of 46 vessels, which comprise product and chemical tankers, harbor tugs, and various offshore supply vessels. The company also operates two Mexican port facilities, Tuxpan and Acapulco, as well as provides port agent services to vessel owners and operators in the Mexican ports. Its logistics business provides trucking services to manufacturers consisting of automobile plants, and retailers, as well as offers logistical f acilities in industrial cities and railroad hubs in Aguascalientes, Toluca, Puebla, Veracruz, Nuevo Laredo, Cuernavaca, Mexico City, Monterrey, Manzanillo, Ensenada, and Altamira. The company's logistics services include consulting, analytical, and logistics outsourcing; logistics network analysis; logistics information process design; trucking, intermodal transport, and auto haulage services; warehousing and bonded warehousing facility management; supply chain and logistics management; product handling and repackaging; local pre-assembly; maintaining and repairing containers; and inbound and outbound distribution using truck transport. Grupo TMM was founded in 1955 and in headquartered in Mexico City, Mexico.

Best Canadian Companies To Watch In Right Now: OM Group Inc.(OMG)

OM Group, Inc. develops, produces, and markets specialty chemicals, advanced materials, and electrochemical energy storage products worldwide. The company operates in three segments: Advanced Materials, Specialty Chemicals, and Battery Technologies. The Advanced Materials segment manufactures inorganic products using unrefined cobalt and other metals and serves the battery materials, powder metallurgy, ceramics, and chemical end markets. It offers cobalt powders, precursors, chemicals, pigments and ceramics, and various raw materials. These products enhance the electrical conduction of rechargeable batteries, as well as strengthen and add durability to diamond and machine cutting tools and drilling equipment. The Specialty Chemicals segment offers electronic chemicals for the printed circuit board, memory disk, general metal finishing, electronic packaging and finishing, and photovoltaic markets. This segment also provides advanced organics comprising additives and driers for paints, and printing inks; rubber adhesion promoters for tires; composite and other catalysts for chemicals; and fuel oil additives, lubricants, and grease additives. In addition, it offers ultra pure chemicals used in the manufacture of electronic and computer components, such as semiconductors, wafers, and liquid crystal displays; and photo-imaging masks, including high-purity quartz or glass plates containing precision, microscopic images of integrated circuits; and reticles for the semiconductor, optoelectronics, and microelectronics industries under the Compugraphics brand name. The Battery Technologies segment provides battery products, primary and secondary batteries, battery management systems, battery chargers, and energetic devices for defense applications; primary and secondary batteries for satellites, aircraft, and the packaging of cells; and miniature batteries to power implantable medical devices. The company was founded in 1991 and is headquartered in Cle veland, Ohio.

Advisors' Opinion:

• [By Zacks]

  OM Group, Inc. (OMG ) is heading toward its third-quarter earnings announcement tomorrow with a great deal of positive momentum. The chemicals company hit new 52-week highs 15 times during October, and its share price rose 30% in the month.

  On Oct 4, this Zacks #1 Rank company raised its outlook for the third quarter to between $2.85 and $2.95, compared to its previous guidance of between $1.45 and $1.65. The move reflects the rise in base metal prices, particularly nickel. OM Group’s previous earnings projection from early August was based on an average nickel price of $11.35 per pound. However, during the third quarter, the price of nickel averaged $13.22 per pound. Over the past 30 days, earnings estimates for this year and next are up approximately 22% and 27% respectively.

Best Canadian Companies To Watch In Right Now: China Metro-Rural Holdings Limited(CNR)

China Metro-Rural Holdings Limited, through its subsidiaries, primarily engages in the development and operation of agricultural logistics and trade centers in northeast China. It also involves in purchasing, processing, assembling, merchandising, and distributing pearls and jewelry products. The company markets its pearls and jewelry products to wholesale distributors and mass merchandisers in Europe, the United States, Hong Kong, and other parts of Asia. In addition, it develops, sells, and leases residential and commercial properties in Hong Kong and the People?s Republic of China. The company is based in Tsimshatsui, Hong Kong.

Advisors' Opinion:

• [By Wyatt Research Staff]

  The stock moved significantly higher in mid-January and traded in a fairly tight range ever since. However, that could change soon. China's agricultural exports to Japan will grow if radiation continues to seep into the food chain.

  China exported $593 million worth of agricultural goods to Japan last year.

Bull of the Day: MDC Holdings (MDC) - Bull of the Day

Earnings estimates have been soaring for MDC Holdings (MDC) as the homebuilder continues to benefit from a rebounding housing market. The significant increase in demand for new homes not only means higher revenues for MDC but also significantly higher profit margins as the company is able to raise prices and reduce incentives while leveraging its fixed expenses.

It is a Zacks Rank #1 (Strong Buy) stock.

MDC Holdings Inc. is a homebuilder that has been building under the name "Richmond American Homes" for 40 years. It primarily operates in the Western and Mountain regions of the United States with some exposure in the Eastern U.S.

The recent rise in interest rates has hurt shares of homebuilders like MDC, but the selloff could be a great buying opportunity as the fundamentals of MDC look very attractive.

Big First Quarter Beat

MDC Holdings reported strong first quarter results on May 2. Earnings per share came in at 45 cents, crushing the Zacks Consensus Estimate of 26 cents. It was a huge increase over the 4 cents it reported in the same quarter last year.

Total revenue surged 77% to $344.3 million, well ahead of the consensus of $294.0 million. Home sale revenues rose a whopping 80% to $331.7 million, which was driven by a 64% jump in home delivered. The average selling price for homes closed rose 9% to $325,900.

The gross profit margin expanded 330 basis points to 17.4% of revenue as the company continued increasing prices and decreasing incentives as demand picked up considerably. Meanwhile, selling, general and administrative expenses fell from 18.5% to 14.5% of revenue as the company leveraged its fixed expenses.

Estimates Soaring

Following solid Q1 results, analysts revised their estimates significantly higher for MDC, sending the stock to a Zacks Rank #1 (Strong Buy). You can see the dramatic rise in earnings estimates in the company's 'Price & Consensus' chart:

The Zacks Consensus Estimate for 2013 is currently $2.49, representing 103% EPS growth over 2012. The 2014 consensus is now $2.65, corresponding with 6% annual growth.

In fact, estimates have been rising in general for homebuilders. The 'Building - Residential / Commercial' industry ranks 8th out of the 265 industries that Zacks ranks. That puts it in the top 3% of all industries.

Reasonable Valuation

Despite strong earnings momentum, shares of MDC have sold off recently as interest rates have risen. But shares look attractive at these levels.

The stock currently trades at just 12.5x 2013 earnings, which is below the industry median of 14.5x. Its price to book ratio of 1.6 is also well below the industry median of 2.0.

The Bottom Line

With very strong industry trends, soaring earnings estimates and reasonable valuation, this homebuilder offers a lot to like.

Todd Bunton is the Growth & Income Stock Strategist for Zacks Investment Research and Editor of the Income Plus Investor service.

Transport ETFs in Focus As UPS Guides Lower - ETF News ...

As is usually the case in the early stages of most market rallies, transportation stocks were leading the way higher for much of 2013. The space saw a great first quarter, though it consolidated in the second quarter thanks to emerging market weakness, and concerns from the Federal Reserve regarding easy money policies.

However, the space has rebounded nicely from the Fed-induced panic in July, racing back towards fresh highs. Yet while optimism is certainly present in the space, it may not last if the recent earnings report from bellwether United Parcel Service (UPS) is any guide.

UPS Warning

The company recently said that it is now expecting earnings for Q2 to come in at $1.13/share, this is below the current Zacks Consensus of $1.19/share, and is actually below the year ago figure as well. The company also slashed full year guidance to a range of $4.65-$4.85 a share, a far cry from current estimates that peg the firm's 2013 earnings at $4.97/share (see 3 Top Ranked Sector ETFs for Earnings Season).

Beyond that, the important company also said that it believes that customers will use cheaper options, possibly pushing away from some of their higher margin options in the future. UPS also stated that they are seeing a bit of a slowdown in the U.S. industrial sector, which could be more bearish news for the not only the firm, but the space in general as well.

Stock Impact

As you might expect, UPS shares were under pressure after this bearish announcement, with shares falling by about 5.3% in the early part of trading. The volume levels were also of note, with more shares trading hands in the first hour than in most normal trading days.



Other companies in the space were also negatively impacted by the report, with arch-rival FedEx (FDX) experiencing above average volume and falling by about 2% as well. Meanwhile, firms like CH Robinson Worldwide (CHRW) and ! Expeditors International (EXPD) also struggled, but their losses were pretty mild compared to both UPS and FDX (See 3 Sector ETFs to Profit from Rising Rates).

ETF Impact

Surprisingly, this wasn't that bad of news for the transportation sector ETFs. Currently, there are two ways to play the space with ETFs, the iShares Dow Jones Transportation Average Fund (IYT) and the SPDR S&P Transportation ETF (XTN) and both of these were down just 0.2% in early Friday trading, despite the duo having both UPS and FDX in their top ten holdings (see the Guide to Transportation ETF Investing).

The two ETFs were thus carried by other components in their holdings, namely railroads and low cost trucking firms. These types of companies were not as heavily impacted by the bearish tone from UPS, and if anything, may have actually benefited from the guidance reduction.

That is because the UPS report suggested that service users would be cycling towards slower, lower margin shipping services for their products. This hurts companies like UPS and FDX for their air freight, but it was welcomed news for those in the relatively slow rail market.

As a result, companies like UNP, KSU, CSX, and NSC were all up on the day, with several firms rising more than 1% on the day. Additionally, both IYT and XTN each have sizable airline and marine components, and these were pretty much unaffected by the UPS news due to their very different industry focuses.

In fact, XTN puts just about 20% in companies classified as 'air freight & logistics' with about 36% in trucking. Meanwhile, IYT has roughly 20% in the delivery service industry, instead putting roughly 31% into the railroad space (see 3 Excellent Dividend ETFs for Safety and Income).

Bottom Line

The allocation profile of both XTN and IYT likely saved the two funds from more severe losses on the day. UPS and its rival FDX faced severe weakness, but the reasons for their slumps were not really pertinent to other fi! rms in th! e transportation sector.

Given this, you probably shouldn't write off transportation ETFs just yet, as the space is clearly well-diversified and can fight through shocks from some of the industry's biggest components. Make sure to watch for railroad and airline earnings later this season though, as weakness here might doom the resilient space, especially after the bearish news from UPS regarding their outlook for the rest of 2013.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Clear Channel and Fleetwood Mac Signed Landmark Revenue-Sharing Agreement (OTCMKTS:CCMO, OTCMKTS:CLNO)

Clear Channel Media & Entertainment (CCMO)

Today, CCMO has shed (-5.17%) down -0.30 at $5.50 with 100 shares in movement thus far (ref. google finance Delayed: 11:54AM EDT June 21, 2013), but don't let this get you down.

Clear Channel Media & Entertainment and Fleetwood Mac previously reported a landmark agreement – the first direct performing rights partnership between a radio company and an artist – that will enable the group to receive revenue from airplay on Clear Channel's digital and broadcast radio platforms. The group's new EP, Extended Play, features the first recording of new Fleetwood Mac music since the release of "Say You Will" over a decade ago.

"Fleetwood Mac has consistently pushed the envelope – creating new sounds, making music that seems designed for radio and looking at the industry in new ways," said Irving Azoff of Azoff Music Management, a representative of the band. "It's fitting that a group that's played such an integral role in radio and music history would be the first band to take such a major step — helping the music industry create a sustainable digital marketplace so it can thrive for decades to come. We're delighted to join Clear Channel in creating a new model for the music industry, one that will be good for performing artists, good for music fans, and good for the people who have invested their talent, time and money."

Take a look at Clear Channel Media & Entertainment (CCMO) 5 day chart:

Cleantech Transit, Inc. (CLNO)

Cleantech Transit, Inc. (OTCMKTS:CLNO) (www.cleantechtransit.net) through its Discovery Carbon subsidiary, develops emissions offset strategies for companies, municipalities, and countries. CLNO currently has surged (+41.00%) up +0.041 at $.141 with 1,334,633 shares in play thus far (ref. google finance Delayed: 1:30PM EDT June 21, 2013). This morning (June 21, 2013), this company hit as low as $.102 and as high as $.148. The fact that their is over a million shares in play thus far only ignites the excitement that CLNO brings to the table.

Today (June 21) CLNO's daily range was at ($.148 – $.102) currently at $.141 would be considered a (+12718.18%) gain above the 52 wk low of $.0011. Eventhough CLNO has surged (+41.00%) up +0.041 at $.141 with 1,334,633 shares in play thus far (ref. google finance Delayed: 1:30PM EDT June 21, 2013), the stock is up +9300% since the concerning dates of December 24, 2013 – June 21, 2013. +9300% is the 6 month high and rightly so.

Earlier this month (June 3), CLNO acquired control of Discovery Carbon Environmental Securities Corporation ("Discovery"). The acquisition advances the strategy of developing significant market share in the alternative clean energy sector. Discovery's proprietary GreenTrees™ for renewable energy, and EvoCert™ environmental credits for offsetting business and individual carbon foot prints are some of the exciting products Discovery provides to clients throughout the world.

CLNO reported today (June 21), that it has acquired 81% of the issued and outstanding shares of Discovery Carbon Environmental Securities Corporation ("Discovery"), a Nevada corporation. The acquisition advances the strategy of developing significant market share in the alternative clean energy sector. Discovery's proprietary GreenTrees™ for renewable energy, and EvoCert™ environmental credits for offsetting business and individual carbon foot prints are some of the exciting products Discovery provides to clients throughout the world.

The Exchange Agreement between the parties required that at least 80% of Discovery's issued and outstanding shares be exchanged for shares of the Company's common stock, in restricted form. The parties are now in the final stages of closing the transaction. As part of the closing of this acquisition, the Company has announced that it will be changing its name to EQCO2, Inc. as well as implementing a 1 for 5 forward stock split for its common stock.

To view EQCO2 video click URL http://www.crwetube.com/media/billy-barnwell-ceo-of-eqco2-talks-about-the-compan

Keep in mind, (June20) CLNO closed at $.10 with 1,644,340 in play (ref. google finance June 20, 2013 – Close). (June19) CLNO closed at $.09 with 1,786,438 in play (ref. google finance June 19, 2013 – Close). (June18) CLNO closed at $.08 with 1,224,685 in play (ref. google finance June 18, 2013 – Close). (June17) CLNO closed at $.06 with 2,681,749 in play (ref. google finance June 17, 2013 – Close). (June14) CLNO closed at $.09 with 4,923,706 in play (ref. google finance June 14, 2013 – Close). (June 13), CLNO closed at $.09 with 2,457,486 in play (ref. google finance June 13, 2013 – Close). (June 12) CLNO closed at $.07 with 2,067,313 in play (ref. google finance June 12, 2013 – Close). (June 11) CLNO closed at $.04 with 1,978,366 in play (ref. google finance June 11, 2013 – Close). (June 10) CLNO closed at $.03 with 1,134,672 in play (ref. google finance June 10, 2013 – Close).

Now take a look at the Cleantech Transit, Inc. (CLNO ) 5 day chart:

Hot Medical Stocks To Buy For 2014

With the medical device industry struggling for growth, leading companies have had to look elsewhere to power up stagnating sales. That's gone beyond expanding their product lines: Some of the best names in the business have looked across the oceans for future growth, where lucrative and untapped emerging markets become tomorrow's medical device battlefields.

British device maker Smith & Nephew (NYSE: SNN  ) is the latest company�to join the emerging markets push. The company announced it agreed to buy Indian trauma device maker Adler Mediequip, which -- along with the buyout of a Brazilian�distribution partner -- totaled around $70 million. What does this mean for your investment and the medical device industry's emerging markets momentum?

Smith & Nephew's well-timed move
Smith & Nephew announced the news on the back of a disappointing earnings report on Thursday. The company's sales slid less than 1%, but that fall is a trend that we've seen plenty of during this earnings season. Medical device companies have had a hard time finding revenue traction with pricing pressures in the industry, although orthopedics-centered firms such as Smith & Nephew have generally done better than the competition.

Hot Medical Stocks To Buy For 2014: Curis Inc.(CRIS)

Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, under collaboration with Genentech, Inc., is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase, epidermal growth factor receptor, and epidermal growth factor receptor 2. In addition, Curis has a development candidate, Debio 0932, which is a Heat Shock Protein 90 or Hsp90 inhibitor. The company holds a license agreement with Debiopharm related to its Hsp90 technologies. Further, it involves in preclinical testing for the development of candidates from its targeted cancer programs. The company was founded in 2000 and is base d in Lexington, Massachusetts.

Advisors' Opinion:

• [By Michael Shulman]

  Curis (NASDAQ: CRIS) has developed a series of cancer treatments based on a technology that disrupts intercellular signaling in the Hedgehog pathway. Disrupting communication disrupts cell duplication, the foundation of tumor growth.

  Curis has more than 20 trials under way with Genentech/Roche and the National Cancer Institute. This year, Genentech will likely report results of a basal cell carcinoma trial for skin cancer, and it has said it will go from this mid-phase trial directly to an application for approval if the results are strong enough.

  One success means a volcanic eruption in the stock, as it will prove the core technology is a viable platform for cancer treatments. A failure could put the entire program — and the company — in jeopardy. I believe the technology will be a success, which means this $2 stock could be worth $40-plus. If I’m wrong, you will probably be looking at a 50-cent stock. I’d say it’s worth the risk.

Hot Medical Stocks To Buy For 2014: Navidea Biopharmaceuticals Inc (NAVB.A)

Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, incorporated in 1983, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company�� radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson�� disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.

Lymphoseek

< p>

Navidea�� pipeline includes clinical-stage radiopharmaceutical agents used to identify the presence and status of disease. Lymphoseek (Kit for the Preparation of Technetium Tc99m for Injection) is a lymph node targeting agent intended for use in intraoperative lymphatic mapping (ILM) procedures and lymphoscintigraphy employed in the overall diagnostic assessment of certain solid tumor cancers. The lymph system is a component of the body�� immune system. The key components of the lymph system are lymph nodes-small anatomic structures that contain disease-fighting lymphocytes, filter lymph of bacteria and cancer cells, and signal infection in response to heightened levels of pathogens. In Navidea�� Phase III clinical studies of Lymphoseek, it detected over 99% of positive nodes identified by vital blue dye (VBD). As of December 31, 2011, Navidea, in co-operation with UC, San Diego affiliate (UCSD), completed or initiated five Phase I clinical trials, one multi-c enter Phase II trial and three multi-center Phase II trial! s ! involving Lymphoseek. Two Phase III studies were completed in subjects with breast cancer and melanoma. During the year ended December 31, 2011, data from NEO3-09 were released, which indicated that all primary and secondary endpoints for the study were met. As of December 31, 2011, third Phase III clinical trial for Lymphoseek in subjects with head and neck squamous cell carcinoma (NEO3-06) was in progress.

AZD4694

AZD4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer's disease (AD). It binds to beta-amyloid deposits in the brain that can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology is a required feature of AD and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD. Patients who are negative for amyloid pathology do not have AD. AZD4694 has b een studied in several clinical trials. Clinical studies through Phase IIa have included more than 80 patients to date, both suspected AD patients and healthy volunteers. No significant adverse events have been observed. Results suggest that AZD4694 has the ability to image patients quickly and safely with high sensitivity.

RadioImmunoGuided Surgery

As of December 31, 2011, RIGScan had been studied in a number of clinical trials, including Phase III studies. Navidea has conducted two Phase III studies, NEO2-13 and NEO2-14, of RIGScan in patients with primary and metastatic colorectal cancer, respectively. Both studies were multi-institutional involving cancer treatment institutions in the United States, Israel, and the European Union.

The Company competes with Pharmalucence, Eli Lilly, Bayer Schering, General Electric and GE Healthcare.

Best Financial Companies To Watch In Right Now: Hemispherx Biopharma Inc (HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.

Ampligen

Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.

Alferon N Injection

Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.

Alferon LDO (Low Dose Oral)

Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.

The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.

Hot Medical Stocks To Buy For 2014: Galena Biopharma Inc (GALE)

Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).

The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.

In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.

The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.

The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.

Is the Market Irrationally Exuberant?

Now that the S&P 500 has broken all-time highs above 1,700, has the stock market’s mood gotten too giddy?

The SPDR S&P 500 ETF (SPY) has climbed 21.04% year-to-date, and that impressive rise has caused people to totally change their mind about stocks.

On Jan. 2, 36% of investors polled described themselves as bears compared to just 18% on July 10, according to the AAII Sentiment Survey. Put another way, the percentage of individual investors that are “bearish” on the U.S. stock market has been cut in half since the beginning of the year. What a reversal!

What about market volatility?

The CBOE S&P 500 Volatility Index (^VIX) is one of the easiest ways to gauge the stock market’s temper. It can tell us a lot. Over the past 12 years, the VIX has moved in the opposite direction as the S&P 500 around 80% of the time.

A depressed VIX can be interpreted as too much complacency or lack of fear in the stock market. Conversely, an elevated VIX infers a high level of anxiety or fear.

In a July 10 post, Michael Moran at the Chicago Board Options Exchange (CBOE) wrote: "Since 1990 the average daily close for the VIX Index was 20.3, but in the first half of 2013: the VIX average daily close was 14.2, and the VIX closed above 20 on only two days – June 20th (at 20.49) and June 24th (at 20.11).”

Really, the last two years have been a period of muted stock market gyrations. Since late 2011, the VIX hasn’t traded above 30.

VIX ETPs like the ProShares VIX Short-Term Futures ETF (VIXY) and the iPath S&P VIX ST Futures ETN (VXX) continue to get crushed. And although the VIX has now marched toward 52-week lows near 11, market volatility is a sleeping giant that never goes away.

What about people going into debt to buy stocks?

NYSE margin debt hit a new all-time high in April, slightly exceeding the previous peak which coincided with the market top in 2007. We know that today’s modernized stock market has many of the safeguards that the 1929 market didn’t have, but excessive speculative borrowing is a red flag in any decade.    

Finally, frenzied penny stock buying is another warning sign.

The dollar volume traded in OTCBB stocks is already at 24,459,441,278 for the first six months of this year compared to just 13,295,767,536 for all of 2012! In other words, the public’s appetite for dicey penny stocks is insatiable.

From a contrarian point of view, none of this means that stocks can’t or won’t continue to rise. Prudence, however, means doing the opposite of the crowd.

Or as Sir John Templeton put it: “Common sense is not common; but common sense and careful logic show that it is impossible or produce superior investment performance if you buy the same assets at the same time as others.”   

---

 The ETF Advisor Pro Newsletter and its Mega Investment Theme Report identifies major market trends along with actionable ETF strategies.

Are you diversifying your portfolio wisely?

These are the words which many of you may have heard often while investing.  Diversification has been widely talked about for the merits it offers, but quite often incorrectly or incompletely followed by many investors.

It is noteworthy that diversification is one of the basic tenets of investment planning, and therefore vouched by many investment advisors. It helps one in reducing the risk to one's portfolio, and thus makes it resilient.  But having said that you need to diversify in a prudent manner which can thus aid you to cushion against the wild swings of the markets.

Very often, through experience we can say that many investors often keep buying various stocks, mutual funds and debt instruments on an ad-hoc basis, and believe that they are diversifying their portfolio. But, in our view unless you don't do it the effective way, it is meaningless and cannot add value to your overall portfolio.

The legendary author on investments- Mr Robert Kiyosaki has so beautifully said, "Your future is created by what you do today, not tomorrow." And thus in context to that, it is indeed imperative that you as investors learn to diversify wisely in the following way:

1. Diversify across asset classes
Yes, it is important to diversify your portfolio across asset classes, since all assets don't move in the same direction. Thus while you may have a high risk appetite and therefore investing in equities, you ought to have exposure to other asset classes- such as debt, gold and real estate as well. This helps you to reduce the overall risk of wealth erosion to your portfolio.

So, say when the Indian equity markets turn turbulent (as they are at present for instance), allocating your hard earned money into debt instruments such as fixed deposits (FDs) and fixed maturity plans (FMPs) can prove to be handy.

However while you diversify across classes, allocate your assets the smart way . Take into account factors such as your age, income, expenses and nearness to goals, which can help you build a rationally diversified portfolio across asset classes. Also, you may follow a diversification model based on your risk profile. Thus say if your willingness to take risk is high (aggressive), you can skew your portfolio more towards the equity asset class. Similarly, if your willingness to take risk is relatively low (conservative), your portfolio can be skewed towards fixed income instruments, and if you are a moderate risk taker you can take a mix of 60:40 into equity and debt respectively.

2. Diversify across investment avenues
Within each asset class too, there is a need to be diversified across various investment avenues. Thus say for example; while your risk profile allows you to participate with a dominant composition towards equities, you ought to diversify well between stocks and mutual fund schemes. Moreover, within stocks and mutual fund schemes too, there needs to be optimal diversification, which can help you to reduce risk as well as create wealth. Hence, care should be taken that you don't over-diversify your portfolio nor make it concentrated either, by holding too many or too little stocks and mutual fund schemes in equity. 
Similarly for debt composition of the portfolio too, care should be taken to diversify across various debt instruments such as bank FDs, corporate FDs, debt mutual funds (suiting your needs) and small savings schemes.

3. Diversify across time horizons
You should hold multiple investment portfolios each catering to a distinct need and running over a commensurate time horizon. For example, as an investor you could have short-term goals (going on a vacation), medium-term goals (buying a house) and long-term goals (providing for retirement). Each of these objectives should be backed by a distinct portfolio and the investments therein should be aligned with the time frames. Equities can account for a higher composition for a long-term portfolio given that they are best equipped to deliver over longer time frames. Conversely, debt instruments could dominate the short-term portfolios.

4. Diversify across issuer of securities
Very often we come across investors who have invested in securities only of some issuers, either believing they are safe, or due to mere penchant for the issuer. It is vital to note that investing is a serious business, and thus it is important to keep emotions at bay and invest rationally.

While you build a portfolio, it is imperative that you diversify across various issuers (i.e. providers or suppliers) of securities, or else you'll be provoking the risk of concentration. Thus for example, although you may be fond of investing in stocks bearing a 'Reliance' tag, you ought to prudently select them through thorough analysis. Likewise in mutual funds schemes as well, you ought to invest across Asset Management Companies (AMCs), and not merely because it comes from a big or renowned fund house. It is noteworthy that each AMC can offer a unique investment style and process, thereby aiding the portfolio on the diversification front. Moreover, it is vital to select winning mutual funds prudently for your portfolio , rather than merely going by what your friends, family and colleagues say.

Similarly while investing in debt instruments too; one should diversify across issuers of securities. Thus for example while you would like to plough your hard earned money into FDs, you should look out for issuers such as various bank and corporates.

5. Diversify across countries
Today, with resident Indians being permitted to invest in assets and securities abroad, subject to the regulations issued by the Reserve Bank of India (RBI), your scope for diversification has further more widened, since you now diversify across countries. However, while undertaking diversification for your portfolio you ought to be cognisant about the economic scenario in the global economy- and more specifically the country which you would like to have exposure to. Also, you got to be well-versed with the tax implications, because unless meaningful tax-adjusted returns aren't obtained, wealth creation would be muted, although one may get a unique diversification edge.   

Don't forget to rebalance your portfolio…
It is noteworthy that any attempt to diversify comes to a zilch, if it is not followed by disciplined portfolio rebalancing. Rebalancing isn't easy and thus many often fail to rebalance their portfolio in the right manner. It involves re-alignment of the portfolio, and what's optimal re-alignment is not known to many. For example you may have suitably diversified your portfolio in accordance to time horizon, by investing for the long-term to take care of your retirement. But unless you don't re-balance your portfolio by shifting from risky asset classes to safer asset classes as you are close to about three years away from your financial goal, you are assuming more risky and may cause harm to your portfolio.

Hence, one should remember that diversification and re-balancing are both integral to the art of investment management and utmost necessary.

PersonalFN  is a Mumbai based Financial Planning and Mutual Fund Research Firm.

Bear of the Day: HomeStreet (HMST) - Bear of the Day

HomeStreet (HMST) missed the mark on the most recent earnings release and has seen estimates drop substantially over the last six months. It is a Zacks Rank #5 (Strong Sell). It is the Bear of the Day.

Mortgage Rates Move Up

Over the last few weeks, interest rates have moved higher and that has caused rates for mortgages to increase as well. Along with a light housing inventory, this will keep some buyers on the sidelines which could hurt the real estate lending business for HMST.

Company Description

HomeStreet (HMST) is a diversified financial services company headquartered in Seattle, WA serving consumers and businesses in the Pacific Northwest, California and Hawaii. The company operates four primary lines of business: Community Banking, Single Family Lending, Commercial Real Estate Lending and Residential Construction Lending. Its principal subsidiaries are HomeStreet Bank and HomeStreet Capital Corporation.

Earnings History

The most recent quarter was a big miss, with the company reporting earnings of $0.74 when the Zacks Consensus Estimate was calling for $0.84. The ten cent negative earnings surprise translates to a 11.9% miss. The topline also came in $5 million light, so another miss of 6% on top.

Besides that quarter, things have been mostly good for HMST. Prior to the earnings miss the company posted four straight positive earnings surprises.

Small Bank

HomeStreet Bank is a WA state chartered savings bank with a network of 23 retail bank branches, 28 stand-alone lending centers and three stand-alone commercial lending centers in Washington, Oregon, California and Hawaii. Its size may keep some investors out of it beyond its limited geographical footprint.

Earnings Estimates Plunge

Estimates for HMST have done nothing but fall all year. The 2013 Zacks Consensus Estimate was $5.40 at the start of the year and that quickly dropped to $5.07 in the following month. By May the number was down to $3.57 and ! it is currently at $2.93. That is a significant decrease in just a little over 6 months.

The 2014 Zacks Consensus Estimate has also been moving lower. It stood at $5.43 in February, but had fallen to $4.12 in May and is currently $3.73.

The question becomes when will estimates stop falling?

Valuation

The valuation picture HMST looks really, really good. That is if can get past the whole negative earnings growth expectations in 2013. The PE multiples of 4.6x trailing and 7.7x forward would make value investors get interested, as would a 1.2x book multiple. But investors need to look past low multiples and understand why they are low before making an investment in a stock like HMST.

The Chart

The year to date chart is one that will turn the stomachs of most investors. The limited footprint of the company can expose it to specific weaknesses that may be seen just in the Pacific Northwest, and that is a risk that many may not want to see. In the more immediate term, the increased rates may help net interest margin, but those rates are likely to change soon.

Brian Bolan is a Stock Strategist for Zacks.com. He is the Editor in charge of the Zacks Home Run Investor service, a Buy and Hold service where he recommends the stocks in the portfolio.

Brian is also the editor of Breakout Growth Trader a trading service that focuses on small cap stocks and also carries a risk limiting strategy. Subscribers get daily emails along with buy, and sell alerts.

Follow Brian Bolan on twitter at @BBolan1

Like Brian Bolan on Facebook

Top Medical Companies To Buy Right Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Steris (NYSE: STE  ) �-- a manufacturer of infection prevention, contamination control, and surgical support products for the health-care industry -- jumped as much as 10% after reporting better-than-expected fourth-quarter results.

So what: For the quarter, Steris' shareholders witnessed revenue increase by 10% to $428.2 million as EPS shrank modestly to $0.70 from $0.76 in the year-ago period. Although Steris blamed European weakness and the medical device excise tax for its weaker bottom-line results, both figures topped the $406 million in revenue and $0.65 in EPS that the Street had been expecting. The biggest boost came from the company's life sciences segment, which saw operating income grow by 14%. For the upcoming year, Steris issued guidance calling for revenue growth of 8%-10% (implying $1.62 billion to $1.65 billion) and EPS of $2.47-$2.60. Current consensus estimates are for revenue of $1.57 billion and EPS of $2.49.

Top Medical Companies To Buy Right Now: Cell Therapeutics Inc (CTIC.A)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisi tion gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed co mplete response compared to patients treated with standard! c! hemotherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links pacli taxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces respons iveness to TMZ. A phase I/II study of OPAXIO combined ! with r! a! diothera! py and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic synd rome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Cel! gene, Tel! ik! , Inc., T! EVA Pharmaceuticals Industries Ltd. and PharmaMar.

Top Medical Companies To Buy Right Now: EntreMed Inc (ENMD.PH)

EntreMed, Inc. (EntreMed), incorporated in 1991, is a clinical-stage pharmaceutical company. EntreMed's drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ENMD-2076 has completed Phase I studies in patients with advanced solid tumors, multiple myeloma and leukemia and is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. The Company�� other product candidates have includes MKC-1, ENMD-1198 and 2-methoxyestrdiol (2ME2, Panzem) for treatment of rheumatoid arthritis.

ENMD-2076 is a novel orally-active, Aurora A/angiogenic kinase inhibitor with potent activity against Aurora A and multiple tyrosine kinases linked to cancer and inflammatory diseases. ENMD-2076 is relatively selective for the Aurora A isoform in comparison to Aurora B. Aurora kinases are key regulators of the process of mitosis, or cell division, and are often over-expressed in human cancers. E NMD-2076 exerts its effects through multiple mechanisms of action, including anti-proliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated significant, dose-dependent preclinical activity as a single agent, including tumor regression, in multiple xenograft models (such as breast, colon, leukemia), as well as activity towards ex vivo-treated human leukemia patient cells.

Best Undervalued Stocks To Invest In 2014: Elan Corporation PLC (ELN)

Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Tysabri

Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.

In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.

Beta Amyloid Immunotherapies (AIP)

Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).

ELND005, an A� Aggregation Inhibitor

The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.

Neotope Biosciences Limited

Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.

Onclave Therapeutics Limited

Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.

The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.

Advisors' Opinion:

• [By Victor Mora]

  Elan is a biotechnology company that is looking for ways to improve and better the lives of people with neurodegenerative and autoimmune diseases. The stock has struggled over the last couple of years and looks to be comfortable at these prices. Over the last four quarters, investors in the company have been disappointed as earnings have decreased while revenue figures have increased. Relative to its peers and sector, Elan has been a year-to-date performance leader. WAIT AND SEE what Elan does in coming quarters.

Top Medical Companies To Buy Right Now: Myriad Genetics Inc (MYGN)

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

As of June 30, 2012, the Company had launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.

Molecular Diagnostic Tests

The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recurrence and measure a patient's exposure to drug therapy to ensu! re optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.

The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.

The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.

Companion Diagnostic Services and Other Revenue

! Through M! yriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company's technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company's menu of biomarkers. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.

The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeutic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.

Legal heir or nominee: Who will inherit your assets?

According to law, a nominee is a trustee and not the owner of the assets. In other words, he is only a caretaker of your assets. The nominee will only hold your asset as a trustee and will be legally bound to transfer it to the legal heirs. For most investments, a legal heir is entitled to the assets of the deceased. A legal heir will be the one whose is mentioned in the will. However, if a will is not made, then the legal heirs of the assets are decided according to the succession laws, where the structure is predefined on who gets how much.

"Nomination is the right to receive, will is the right to own except in case of equity shares where nomination prevails," Mashruwala added.

Below is the edited transcript of the interview

Q: What is the difference between a will and a nomination? What are the circumstances under which either should be used?

A: From simple man's language perspective, a nominee is somebody who receives the asset upon death of a person. However, the nominee cannot own it. Let me simplify that. Say, if a husband has nominated his mother in life insurance policy. Upon his death, the entire proceeds of life insurance will go to the mother, but the mother can't own it if a will has something contrary written. If the will says that a portion of or the entire asset should go to his wife and children then the mother will have to part with that.

Nomination, in simple language, is the right to receive. But a will shall decide who will eventually own the asset. In case there is no will then there is Indian Succession Act, Hindu Law, Mohemmadan Law etc. Summing up, nomination is the right to receive, will is the right to own except in case of equity shares where nomination prevails.

Q: If a person were to nominate for all his assets, would he then need a will?

A: If, for example, a person has said that he is nominating all his assets to his brother, but in a will, he writes something different or if there is no will then based on the Indian Succession Act, Hindu Law or Mohemmadan Law, the brother will receive all the assets but he will have to distribute it. If there is a will and it says that the entire asset will go to his brother, then the brother will own it. But if the will says anything contrary, the brother will probably more act as a trustee holding onto assets till the final will is out. If there is no will then the nominee will hold onto the assets and it becomes his.

1 2

Watch Video

Excerpts from Markets and Macros on CNBC-TV18 Watch the full show »

.ftCnbcShare{border-top:#d1d1d1 1px solid; padding:8px;margin-bottom: -27px; margin-top:10px;}

Markets And Macros at 11:00 am

Tweet

Share on Tumblr

SHARE . EMAIL

.gD_15nRedN{font:15px/20px Arial;color:#FF0000 !important;text-decoration:none;font-weight:normal;}

Related News

What if 'Karta' in Hindu Undivided Family passes away? IRDA eases short tenor life insurance norms: What it means 

.gD_15nRed{font:15px/20px Arial;color:#FF0000 !important;text-decoration:none;font-weight:bold;}

.GoogleNewsTitle{font:14px/16px Trebuchet MS,Arial,Helvetica,sans-serif;color:#005066;text-decoration:none;} .GoogleNewsTitle:hover{text-decoration:underline} .GoogleNewsURL{font:12px Trebuchet MS,Arial,Helvetica,sans-serif;color:#000;text-decoration:none;} .GoogleNewsURL:hover{text-decoration:underline} .GoogleNewsTitleLine{font:20px/22px Trebuchet MS,Arial,Helvetica,sans-serif;color:#F01414;text-decoration:none} .GoogleNewsTitleLine:hover{text-decoration:underline} .GoogleNewsLineURL{font:12px family:Trebuchet MS,Arial,Helvetica,sans-serif;color:#000;text-decoration:none} .GoogleNewsLineURL:hover{text-decoration:underline}

Tags: CNBC-TV18, Gaurav Mashruwala, Financial Planner, assets

No intent to control capital; fund-raising door open: FM

No intent to control capital; fund-raising door open: FM

.scroll_hv .panel{width:250px !important; padding:10px 10px 25px !important} #scroll13{width:540px;} .hv_bx{margin-left:-10px;} .tab_data1{padding:0px;}

Do You Smell Smoke in Tobacco Stocks?

Yield chasing has pushed tobacco stocks' valuations to their multiyear highs, while the dividend yields from the stocks are at multiyear lows. While income investors do not have a lot of options left by the historical low bond yields, they may want to watch out. Don't forget Warren Buffett's rule number one while the party is going on nicely. Tobacco stocks have been very rewarding to investors. They are less volatile, and they generate far fatter dividends than bonds. But investors need to be aware that the dividend yield of tobacco stocks are at decade lows, while their valuations are at decade highs. Historically, valuations tend to reverse to their means.

The decade low yield of tobacco stocks can be clearly seen from our new interactive charts, which are embedded below. The chart shows the dividend yield of three tobacco stocks: Reynolds American (RAI), Philip Morris International (PM) and British American Tobacco (BTI).

BTI,RAI,PM yield Interactive Chart

In 2003, when the tobacco industry was threatened by another large litigation risk, the dividend yield of Reynolds American (RAI) was at 13%. In the market crash of 2008-2009, the yield was more than 10%. Today it is at a little above 5%. While 5% is high compared with the market average, only in 2005-2007 the yield was lower than its current value. We know what happened after 2007, the stock declined more than 30% in from 2008 to the first quarter of 2009.

The situation is even worse with Philip Morris International (PM) and British American Tobacco (BTI). The yields for both of them are at their historical lows.

Owning tobacco stocks has certainly been rewarding to investors. Besides generating nice dividends, the stock prices have also outperformed the market significantly since the last market peak in 2007. While the S&P500 is still below its peak, tobacco stocks have made new highs. See the price chart below for Reynolds American (RAI), Philip Morris International (PM) and British American Tobacco (BTI)! .

BTI,RAI,PM Interactive Chart

While everything has gone well, the valuations are at their highest level. See the historical P/E of these three companies below:

BTI,RAI,PM pe Interactive Chart

A historical high valuation is usually followed by a reversion to the mean.

Top Clean Energy Companies To Invest In 2014

After huge gains yesterday, the Dow Jones Industrial Average (DJINDICES: ^DJI  ) is on the move once again. The index is up 67 points as of 11:35 a.m. EDT following positive jobs numbers after last week's disappointing reports. And though the tech sector had been some of the driving force behind the Dow's climb over the past two days, some bad news has caused many of the Dow's big players to fall.

Last week was a rough one for the labor market, which had to bear the brunt of three negative jobs reports. With today's jobless claims release, investors are getting a breather from the bad news. Claims from last week fell sharply to 346,000 -- a 42,000 drop. This follows last week's huge jump to 388,000 claims, which was way over analyst expectations. This week's numbers fell below expectations, giving the markets some added fuel this morning.

Top Clean Energy Companies To Invest In 2014: OBA Financial Services Inc.(OBAF)

OBA Financial Services, Inc. operates as the bank holding company for OBA Bank that provides financial services to individuals, families, and businesses in the United States. The company offers various deposit accounts, including statement savings accounts, certificates of deposit, money market accounts, commercial and regular checking accounts, and individual retirement accounts. Its loan portfolio comprises one- to four-family residential mortgage loans, commercial real estate loans, home equity loans and lines of credit, commercial business loans, construction loans, and consumer loans. The company provides its services through a main office and four full-service branches located in Montgomery County and Howard County, Maryland; and Washington, D.C. OBA Financial Services, Inc. was founded in 1861 and is headquartered in Germantown, Maryland.

Top Clean Energy Companies To Invest In 2014: ABIOMED Inc.(ABMD)

Abiomed, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company?s products are designed to enable the heart to rest, heal, and recover by enhancing blood flow and/or performing the pumping function of the heart. Its products consist of Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The company also manufactures and sells the AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. Its products are used in the cardiac catheterization lab by interventional cardiologists and/or in the heart surgery suite by heart surgeons. The company sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, the United Kingdom, and internationally. Abiomed, Inc. was founded in 1981 and is based in Danvers, Massachusetts.

Hot Growth Stocks To Watch For 2014: Putnam Municipal Opportunities Trust(PMO)

Putnam Municipal Opportunities Trust is a closed ended fixed income mutual fund launched and managed by Putnam Investment Management, LLC. It invests in fixed income markets of United States. The fund invests in companies operating across healthcare, utilities, transportation, water and sewer, and housing sectors. Putnam Municipal Opportunities Trust was formed in 1993 and is domiciled in United States.

Top Clean Energy Companies To Invest In 2014: Ardea Biosciences Inc.(RDEA)

Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout and cancer in the United States. Its product candidates include Lesinurad (RDEA594), an inhibitor of the URAT1 kidney transporter, which is in Phase III clinical trials for the treatment of gout; BAY 86-9766 (RDEA119), a mitogen-activated ERK kinase (MEK) inhibitor that is in Phase II clinical trials for the treatment of cancer; and RDEA3170, an URAT1 kidney transporter inhibitor, which is in Phase I clinical trials for the treatment of gout. The company has a development and commercialization license agreement with Bayer Healthcare AG to develop and commercialize MEK inhibitors for various indications. Ardea Biosciences, Inc. is based in San Diego, California.

Top Clean Energy Companies To Invest In 2014: Westpac Banking Corporation(WBC.AX)

Westpac Banking Corporation provides various banking and financial services. The company offers financial services, such as lending, deposit taking, payments, investment portfolio management and advice, unit trust and superannuation fund management, insurance, leasing, general finance, foreign exchange, and money market services. Its deposit products include term deposits, savings accounts, and business transactional accounts. The company?s loan portfolio comprises advances, overdrafts, home loans, credit card and other personal lending, term loans, leasing receivables, bill financing, and redeemable preference share financing and acceptances. It also offers investment, superannuation, and retirement products; investment platforms, such as wrap and master trusts; private banking and financial planning services; and insurance solutions, including the manufacture and distribution of life, general, and lenders mortgage insurance and deposit bonds. In addition, the company pr ovides various services, such as advice for cash flow finance, trade finance, automotive and equipment finance, property finance, agribusiness finance, transaction banking, and treasury services. Westpac Banking Corporation serves consumer, small and medium enterprise, commercial, corporate, institutional, and government customers through branches, third party distributors, call centers, automated teller machines, electronic funds transfer point of sale, terminals, telephone banking and Internet banking channels, business banking centers, home finance managers, and specialized consumer and business relationship managers. As of September 30, 2011, it operated 1,532 branches primarily in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Bank of New South Wales and changed its name to Westpac Banking Corporation in 1982. Westpac Banking Corporation was founded in 1817 and is headquartered in Sydney, Australia.

Top Clean Energy Companies To Invest In 2014: Neratelecommunications Ltd (N01.SI)

Nera Telecommunications Ltd designs, engineers, sells, distributes, installs, services, and maintains telecommunication systems and products in transmission networks, and satellite communications and information technology networks. Its Telecommunications segment offers wireless infrastructure network solutions, including in-building, outdoor coverage enhancement, RF access network optimization, benchmarking, 3G/LTE base stations, and point-to-point and point-to-multi-point microwave solutions; and undertakes various projects that comprise planning, designing, installation, commissioning, testing, and post sales support and services for various market sectors, such as ISPs, broadcasters, enterprises, government organizations, offshore, and utilities. This segment also provides satellite communications products comprising land and marine terminals, land earth stations/gateways, broadband satellite networks for B2B applications, satellite airtime, on-board marine service, an d after sales services to satellite service providers, ISPs, government/aid/rescue organizations, enterprises, media, and marine/offshore/oil and gas industries. Its Infocomm segment offers IP network infrastructure products, such as routers, switches, security and application performance products, and access controlling products; digital TV broadcast network infrastructure products, networks, and services to the broadcasters and service providers; and optical network platform solutions to service providers, mobile carriers, business enterprises, multi-service operators, government, transport, and utilities. This segment also provides point-of-sale payment terminals; terminal/application software; and wireless, contact-less, and IP products to network devices. It serves customers in Singapore, Indonesia, Thailand, the Philippines, Vietnam, Malaysia, and other Asian countries. The company is based in Singapore.

EUR/USD scope for movement up to 1.3417

FXstreet.com (New York) - The EUR/USD foreign exchange rate has seen its rally falter at the 1.3360 region Thursday morning during US trading, as this level has seemingly derailed any prolonged attempts higher thus far.

In the United States, Initial Jobless Claims (August 3) were reported at 333K, beating expectations of 336K. Moreover, Continuing Jobless Claims (July 27) yielded a figure of 3.018M, relative to a projection of 2.950M.

EUR/USD strategic bias

According to Karen Jones, an analyst at Commerzbank, "EUR/USD has started to erode the 2013 resistance line currently at 1.3327 - directly overhead lies the key resistance at 1.3346/1.3417. This is where the 2011-2013 downtrend, the 200-week MA and the June high meet and we look for it to hold the topside and provoke failure. Loss of last weeks low at 1.3188 is needed to alleviate immediate upside pressure. Intraday charts are suggesting the 1.3417 high will be tested, but that it is likely to hold."

EUR/USD technical levels

At the time of writing, the EUR/USD is presently operating at 1.3360 Thursday, climbing at a rate of +0.18% above its opening. Having settled after its initial spark towards 1.3370 (intraday high), the pair has maintained a far narrower path around the 1.3360 region. Technically speaking, the EUR/USD is constrained by resistances at 1.3362, onto 1.3396, and finally 1.3446, calculates the Mataf.net analyst team.